Imiglucerase (Cerezyme, Genzyme) is a recombinant form of algulcerase, a glucocerebrosidease derived from placentas. This can be used to treat patients with Gaucher's disease who meet certain criteria.


Criteria for the use of enzyme replacement therapy with Imiglucerase - one or more of the following:

(1) pulmonary involvement

(2) growth retardation (reduced height or weight for age) AND clinical malnutrition

(3) persistent or increasing autoimmune disease

(4) a sibling with a rapid acceleration in the course of the disease

(5) clinical onset at < 5 years of age

(6) splenomegaly with hypersplenism and pancytopenia lasting >= 3 months

(7) hepatomegaly with abnormal liver function tests

(8) symptomatic anemia due to bone marrow involvement (not due to iron deficiency or other identifiable cause)

(9) thrombocytopenia with bleeding AND/OR declining counts

(10) bone involvement with bone pain, spinal compression and/or other serious finding

(11) molecular diagnosis of a severe genotype (except homozygosity for N370S) AND symptomatic



• Pancytopenia involves leukopenia (WBC < 3,000 per µL), anemia (hemoglobin < 9 g/dL), and thrombocytopenia (< 50,000 per µL)


To read more or access our algorithms and calculators, please log in or register.